Microsaic Systems plc
("Microsaic" or the "Company")
Appointment of WH Ireland as Joint Broker
Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce the appointment of WH Ireland Limited as Joint Broker with immediate effect, alongside N+1Singer as Nominated Adviser and Joint Broker.
Enquiries:
|
Microsaic Systems plc |
+44 (0) 1483 751 577 |
|
Glenn Tracey, CEO |
|
|
Bevan Metcalf, FD |
|
|
N+1 Singer (Nominated Adviser & Joint Broker) |
+44 (0)20 7496 3000 |
|
Aubrey Powell / George Tzimas (Corporate Finance) |
|
|
Tom Salvesen (Corporate Broking) |
|
|
WH Ireland Limited (Joint Broker) |
+44 (0)20 7220 1666 |
|
James Joyce |
|
|
Jasper Berry |
|
|
IFC Advisory Ltd (Financial PR) |
+44 (0)20 3934 6630 |
|
Graham Herring |
|
|
Florence Chandler |
About Microsaic Systems
Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing, and have applications in environmental testing, chemical reaction monitoring, and academic teaching. The Company is working with a range of established global life science OEM partners, distributors and research organisations to co-develop and commercialise new solutions to improve productivity in the development of small molecule and novel biologic medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification and purity.
Microsaic's core products, the 4500 MiD®, and MiD®ProteinID are robust and compact MS systems, retaining the functionality of larger conventional MS systems, easier to use by non-specialists, consuming less energy and having lower running costs. For more information, please go to www.microsaic.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.